Clinical Trial Update: Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial of dovitinib lactate for pancreatic neuroendocrine tumors has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrinoma
• Glucagonoma
• Insulinoma
• Islet Cell Carcinoma
• Pancreatic Neuroendocrine Tumor
• Pancreatic Polypeptide Tumor
• Somatostatinoma

Drugs mentioned

• Dovitinib lactate (dovitinib)

Snippet

Sponsor: Academic and Community Cancer Research United | Conditions: Gastrinoma, Glucagonoma | Phase 2 | Status: WITHDRAWN